Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and connected persons in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share acquisition transactions.
Material Changes
On September 9, 2014, the following individuals acquired GSK Ordinary Shares through the GSK ShareReward Plan at a price of 1434.34 pence per share:
- Directors/PDMR: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Connected Person: Mrs K Thomson (connected to Mr P C Thomson).
Acquisitions consisted of shares under both the personal contribution element and the matching element (GSK contribution) of the plan. Most participants acquired 9 shares in each element, while Dr P J T Vallance acquired 8 shares in each element, and Mrs K Thomson acquired 1 share in each element.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares acquired by each Director and PDMR listed in the ShareReward Plan.
- Confirm the transaction price of 1434.34 pence per Ordinary Share against market data for September 9, 2014.
- Review the specific terms of the GSK ShareReward Plan regarding personal contributions and matching elements.